NVCT SEC-arkiveringar - Nuvectis Pharma, Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1875558

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nuvectis Pharma, Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVE
August 5, 2025	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights · NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminent · Strengthened cash position following a July At-T
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2025 Nuvectis Pharma, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 Nuvectis Pharma, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
May 9, 2025	424B5	Up to $60,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-270657 PROSPECTUS SUPPLEMENT (to Prospectus dated March 29, 2023) Up to $60,000,000 Common Stock We have entered into a Sales Agreement, dated May 9, 2025 (the “Sales Agreement”), with Leerink Partners LLC (“Leerink Partners”), relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the Sale
May 9, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2405
May 9, 2025	EX-10.1	Sales Agreement, dated May 9, 2025, by and between Nuvectis Pharma, Inc. and Leerink Partners LLC. Exhibit 10.1 Nuvectis Pharma, Inc. Shares of Common Stock ($0.00001 par value per share) SALES AGREEMENT May 9, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1.     Issuance an
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUV
May 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2405
May 6, 2025	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights · NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 AACR conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategy · Completed
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 25, 2025	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights · NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025 · NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program
February 25, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS
February 25, 2025	EX-4.6	Description of Securities of Nuvectis Pharma, Inc. * EXHIBIT 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms “we,” “our,” “us,” and “Nuvectis,” refer to Nuvectis Pharma, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of our capital stock. As it is only a summary, it does not contain all the information that m
February 25, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 8
February 25, 2025	EX-21.1	List of subsidiaries of Nuvectis Pharma, Inc. * EXHIBIT 21.1 NUVECTIS THERAPEUTICS INC. List of Subsidiaries Nuvectis Pharma, Inc. does not have any subsidiaries.
February 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 Nuvectis Pharma, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86
February 6, 2025	EX-99.1	Nuvectis Pharma Announces Proposed Public Offering of Common Stock Exhibit 99.1 Nuvectis Pharma Announces Proposed Public Offering of Common Stock FORT LEE, NJ, February 4, 2025 – Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that it has commenced an underwritten public offering
February 6, 2025	EX-1.1	Underwriting Agreement dated February 5, 2025, between Nuvectis Pharma, Inc. and Lucid Capital Markets, LLC. Exhibit 1.1 Execution Version 2,700,000 Shares of Common Stock Nuvectis Pharma, Inc. UNDERWRITING AGREEMENT February 5, 2025 Lucid Capital Markets, LLC 570 Lexington Ave 40th floor New York, New York 10022 Ladies and Gentlemen: Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Lucid Capital Markets, LLC
February 6, 2025	EX-99.2	Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock Exhibit 99.2 Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock FORT LEE, NJ, February 5, 2025 – Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the pricing of its previously announce
February 6, 2025	424B5	2,700,000 Shares of Common stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-270657 PROSPECTUS SUPPLEMENT (to Prospectus dated March 29, 2023) 2,700,000 Shares of Common stock We are offering 2,700,000 shares of our common stock, par value $0.00001 per share, in this offering. Our common stock is listed on The Nasdaq Capital Market under the symbol “NVCT”. On February 4, 2025 the last reported sale price of our common s
February 4, 2025	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 4, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-270657 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a
January 3, 2025	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) NUVECTIS PHARMA, INC.
January 3, 2025	S-8	As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 File No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl
November 5, 2024	EX-99.1	NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights · Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers · NXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts com
November 5, 2024	SC 13G/A	NVCT / Nuvectis Pharma, Inc. / Pontifax Management 4 G.p. (2015) Ltd. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0220038-13a1gponti4nuve.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) September 30, 2024 (Date of Event Which Re
November 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86
November 5, 2024	10-Q	On the Microsoft license do we have access to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents On the Microsoft license do we have access to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 29, 2024	EX-99.1	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Exhibit 99.1 Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers August 29, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the t
August 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2024 Nuvectis Pharma, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-
August 6, 2024	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights August 6, 2024, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported it
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVE
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Nuvectis Pharma, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2
June 13, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
May 7, 2024	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEET (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights · Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA · Data presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell lines · Severa
May 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2405
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUV
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm
April 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
March 5, 2024	EX-97.1	Clawback Policy* Exhibit 97.1 NUVECTIS PHARMA, INC. INCENTIVE COMPENSATION RECOVERY POLICY 1.0 Effective Date; Acknowledgement. 1.1 Nuvectis Pharma, Inc. (the “Company”) has adopted this Policy in accordance with the applicable listing standards of Nasdaq and Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which require listed companies to adopt and comply with a compensation
March 5, 2024	EX-21.1	List of subsidiaries of Nuvectis Pharma, Inc. * EXHIBIT 21.1 NUVECTIS THERAPEUTICS INC. List of Subsidiaries Nuvectis Pharma, Inc. does not have any subsidiaries.
March 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS
March 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2024 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
March 5, 2024	EX-19.1	Nuvectis Pharma, Inc. Insider Trading Policy * Exhibit 19.1 NUVECTIS PHARMA, INC. INSIDER TRADING POLICY I.SUMMARY OF POLICY All rules set forth in this Policy apply to all directors, officers, and employees of Nuvectis Pharma, Inc. (the “Company”). This Policy also applies to family members who reside in the same household as the director, officer or employee, other members of a person’s household and persons and entities controlled by a pers
March 5, 2024	EX-4.6	Exhibit 4.6, which is contained in our Annual Report on Form 10-K filed with the SEC on March 5, 2024 EXHIBIT 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms “we,” “our,” “us,” and “Nuvectis,” refer to Nuvectis Pharma, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of our capital stock. As it is only a summary, it does not contain all the information that m
March 5, 2024	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights · NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the FDA · NXP800 Investigator-sponsored clinical trial in cholangiocarcinoma initiated with the Mayo Clinic ·
February 28, 2024	SC 13G/A	NVCT / Nuvectis Pharma, Inc. / Mosseri Marlio Charles - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 6, 2024	SC 13G	NVCT / Nuvectis Pharma, Inc. / Pontifax Management 4 G.p. (2015) Ltd. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. )* Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 1, 2024	SC 13G/A	NVCT / Nuvectis Pharma, Inc. / Shemesh Shay - SC 13G/A Passive Investment SC 13G/A 1 tm244794d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Ch
February 1, 2024	SC 13G/A	NVCT / Nuvectis Pharma, Inc. / Poradosu Enrique - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
January 31, 2024	SC 13G/A	NVCT / Nuvectis Pharma, Inc. / Peters Thomas Phineas - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
November 8, 2023	10-Q	315603 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents 315603 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2023	EX-99.1	NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights · Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing · Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid Tumors · NXP800 Granted Orphan Drug Designation for the Treatment of Cholangiocarcinoma · NXP800 Ph
November 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86
September 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2023 Nuvectis Pharm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number)
September 12, 2023	EX-99.1	Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial Exhibit 99.1 Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial September 12, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation
August 17, 2023	EX-99.1	Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma Exhibit 99.1 Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in
August 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2023 Nuvectis Pharma, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 17, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-
August 9, 2023	EX-99.1	Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights Exhibit 99.1 Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights · The Phase 1b study of NXP800 in patients with platinum resistant, ARID1a-mutated ovarian carcinoma is ongoing · NXP900 IND cleared by the US FDA, start of Phase 1a study expected in Q3 2023 August 9, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a cl
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVE
August 9, 2023	S-8	As filed with the Securities and Exchange Commission on August 9, 2023 As filed with the Securities and Exchange Commission on August 9, 2023 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I
August 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2
August 9, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) NUVECTIS PHARMA, INC.
July 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 Nuvectis Pharma, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
June 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 Nuvectis Pharma, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Nuvectis Pharma, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-240
May 15, 2023	EX-99.1	Nuvectis Pharma Announces FDA Clearance of NXP900 IND Exhibit 99.1 Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administratio
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUV
May 10, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-240
May 10, 2023	EX-99.1	NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights · Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer Initiated · IND and Phase 1a Study for NXP900 Pending · In-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR Conference Demonstrates Potential of NXP800 in the Treatment of Cholangiocarcinoma May 1
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
April 3, 2023	SC 13G	NVCT / Nuvectis Pharma Inc / Peters Thomas Phineas - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) February 4, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
March 27, 2023	CORRESP	March 27, 2023 March 27, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
March 27, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECT
March 17, 2023	EX-1.2	At The Market Offering Agreement, between Nuvectis Pharma, Inc., and H.C. Wainwright & Co., LLC, dated March 17, 2023 (filed herewith) Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT March 17, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Nuvectis Pharma, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1.             Definitions. The terms that follow, when u
March 17, 2023	S-3	As filed with the Securities and Exchange Commission on March 17, 2023. As filed with the Securities and Exchange Commission on March 17, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 86-2405608 (I.R.S. E
March 17, 2023	EX-4.6	Form of Indenture (filed herewith) Exhibit 4.6 NUVECTIS PHARMA, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Act Section Indenture Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 §311 11.01(f), 16.02 §312 14.02(d), 16.02 (b) 11.10
March 17, 2023	EX-FILING FEES	Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nuvectis Pharma, Inc.
March 8, 2023	EX-21.1	List of subsidiaries of Nuvectis Pharma, Inc. * EXHIBIT 21.1 NUVECTIS THERAPEUTICS INC. List of Subsidiaries Nuvectis Pharma, Inc. does not have any subsidiaries.
March 8, 2023	EX-4.6	Description of our common stock, which is contained in our Annual Report on Form 10-K filed with the SEC on March 8, 2023 EXHIBIT 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms “we,” “our,” “us,” and “Nuvectis,” refer to Nuvectis Pharma, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of our capital stock. As it is only a summary, it does not contain all the information that m
March 8, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2023 Nuvectis Pharma, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 7, 2023 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
March 7, 2023	EX-99.1	NUVECTIS PHARMA, INC. BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights · NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma · ENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer (Study Commencement Pending) · NXP900 IND Submission and Phase 1 Study Commencement Expected in
February 13, 2023	SC 13G	NVCT / Nuvectis Pharma Inc / Shemesh Shay - SC 13G Passive Investment SC 13G 1 tm236504d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
February 13, 2023	SC 13G	NVCT / Nuvectis Pharma Inc / Poradosu Enrique - SC 13G Passive Investment SC 13G 1 tm236504d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
January 9, 2023	SC 13G/A	NVCT / Nuvectis Pharma Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment SC 13G/A 1 tm232243d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Ch
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2022	EX-99.1	NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights ? The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 ? Investigational New Drug Application(?IND?)-enabling studies for NXP900 are ongoing, submission of IND or equivalent expected in Q1 2023 ? P
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86
August 23, 2022	CORRESP	August 23, 2022 August 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 15, 2022	S-1	As filed with the U.S. Securities and Exchange Commission on August 15, 2022. As filed with the U.S. Securities and Exchange Commission on August 15, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 86-2405608 (State of incorporation (Primary Standard Industrial (I.R.S.
August 15, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Nuvectis Pharma, Inc.
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2022	EX-99.1	NUVECTIS PHARMA, INC. CONDENSED BALANCE SHEETS (USD in thousands, except per share and share amounts) Exhibit 99.1 Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights ? NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023 ? NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in the Clinical Program ? NXP900 IND-Enabling Work Progressing as Planned, Expected Completion
August 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2
July 29, 2022	EX-10.2	Form of Preferred Investment Option, filed as exhibit 10.2 to the Form 8-K filed on July 29, 2022 and incorporated herein by reference. EX-10.2 3 tm2222131d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED O
July 29, 2022	EX-99.1	Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement Exhibit 99.1 Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement July 27, 2022, Fort Lee, NJ - Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, announced today that it has entered into definitive agreements with healthca
July 29, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-24
July 29, 2022	EX-10.4	Form of Registration Rights Agreement by and among Nuvectis Pharma, Inc. and the Purchasers, dated July 27, 2022. Exhibit 10.4 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of July 27, 2022, by and between Nuvectis Pharma, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Secu
July 29, 2022	EX-10.3	Form of Pre-Funded Warrant, filed as exhibit 10.3 to the Form 8-K filed on July 29, 2022 and incorporated herein by reference. EX-10.3 4 tm2222131d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED O
July 29, 2022	EX-10.1	Form of Securities Purchase Agreement by and among Nuvectis Pharma, Inc. and the Purchasers, dated July 27, 2022. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 27, 2022, between Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-240
May 11, 2022	EX-99.1	Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on the Horizo Exhibit 99.1 Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR ?New Drugs on the Horizon? Session NXP900 Preclinical Potency Against Various Types of Cancer Cells of Squamous Origin Presented at the 2022 AACR Meeting Complet
March 29, 2022	SC 13G/A	NVCT / Nuvectis Pharma Inc / Mosseri Marlio Charles - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 67080T108 (CUSIP Number) March 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
March 28, 2022	SC 13D	NVCT / Nuvectis Pharma Inc / BENTSUR RON - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. ) Under the Securities Exchange Act of 1934 nuvectis pharma, inc. (Name of Issuer) Common Stock, $0.00001 Par Value (Title of Class of Securities) 67080T108 (CUSIP Number) Ron Bentsur 1 Bridge Plaza Suite 275 Fort Lee, NJ 07024 (201) 614-3151 (Name, Address and Telephone Number of Person Authorized
March 24, 2022	S-8	As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I
March 24, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Nuvectis pharma, Inc.
March 23, 2022	EX-21.1	List of subsidiaries of Nuvectis Pharma, Inc. * EXHIBIT 21.1 NUVECTIS THERAPEUTICS INC. List of Subsidiaries Nuvectis Pharma, Inc. does not have any subsidiaries.
March 23, 2022	EX-4.3	Description of Securities of Nuvectis Pharma, Inc. * EXHIBIT 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 When used herein, the terms ?we,? ?our,? ?us,? and ?Nuvectis,? refer to Nuvectis Pharma, Inc. DESCRIPTION OF CAPITAL STOCK The following description summarizes the material terms of our capital stock. As it is only a summary, it does not contain all the information that m
March 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS PHARMA, INC. (E
March 22, 2022	8-K	Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86-2
March 22, 2022	EX-99.1	Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated of Phase 1a Clinical Trial for NXP800 Announced Promising D Exhibit 99.1 Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated of Phase 1a Clinical Trial for NXP800 Announced Promising Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase Loss Announced Upcoming Oral and Poster
February 15, 2022	SC 13G	NVCT / Nuvectis Pharma Inc / Mosseri Marlio Charles - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nuvectis Pharma, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) N/A (CUSIP Number) February 8, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 7, 2022	424B4	Per share TABLE OF CONTENTS ?Filed Pursuant to Rules 424(b)(4) and 462(b)? ?Registration Nos.
February 4, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tm2134227d2ex107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-1MEF (Form Type) Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fe
February 4, 2022	EX-3.1	Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as exhibit 3.1 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. Nuvectis Pharma, Inc., originally named Centry Pharma, Inc., a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the ?Corporation?) does hereby certi
February 4, 2022	S-1MEF	As filed with the U.S. Securities and Exchange Commission on February 4, 2022. As filed with the U.S. Securities and Exchange Commission on February 4, 2022. Registration No. 333 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 86-2405608 (State of incorporation or organization) (Primary Standard
February 4, 2022	EX-3.2	Amended and Restated Bylaws of Nuvectis Pharma, Inc., filed as exhibit 3.2 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference. EX-3.2 4 tm2134227d1ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 amended and restated BYLAWS OF nuvectis PHARMA, INC. amended and restated BYLAWS OF nuvectis PHARMA, inc. Article I OFFICES Section 1.1 Offices. The address of the registered office of Nuvectis Pharma, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be at 251 Little Falls Drive, Wilmington, New Castle County, Delaware
February 4, 2022	EX-1.1	Underwriting Agreement, dated February 4, 2022, between Nuvectis Pharma, Inc. and H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein. EX-1.1 2 tm2134227d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between NUVECTIS PHARMA, INC. and H.C. WAINWRIGHT & CO., LLC as Representative of the Several Underwriters Nuvectis Pharma, Inc. UNDERWRITING AGREEMENT New York, New York February 4, 2022 H.C. WAINWRIGHT & CO., LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 430 Park Avenue, 3rd Floor
February 4, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 Nuvectis Pharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-41264 (Commission File Number) 86
February 4, 2022	EX-3.3	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as exhibit 3.3 to the Form 8-K filed on February 4, 2022 and incorporated herein by reference. Exhibit 3.3 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Nuvectis Pharma, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of Incorporation
February 3, 2022	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 NUVECTIS PHARMA, INC. (Exact name of registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1 Bridge Plaza, Suite 275 Fort Lee, NJ (Address of principal exe
February 2, 2022	CORRESP	430 Park Avenue \| New York, NY 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC February 2, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
February 2, 2022	CORRESP	February 2, 2022 February 2, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
January 24, 2022	S-1/A	As filed with the U.S. Securities and Exchange Commission on January 21, 2022. ? ?As filed with the U.S. Securities and Exchange Commission on January 21, 2022. Registration No. 333-260099? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-2405608 ? ? (State
January 18, 2022	S-1/A	As filed with the U.S. Securities and Exchange Commission on January 14, 2022. TABLE OF CONTENTS ?As filed with the U.S. Securities and Exchange Commission on January 14, 2022. Registration No. 333-260099? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-24
January 18, 2022	EX-1.1	Form of Underwriting Agreement. EX-1.1 2 tm2134024d8ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between NUVECTIS PHARMA, INC. and H.C. WAINWRIGHT & CO., LLC as Representative of the Several Underwriters Nuvectis Pharma, Inc. UNDERWRITING AGREEMENT New York, New York [], 2022 H.C. WAINWRIGHT & CO., LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 430 Park Avenue, 3rd Floor New Yor
January 18, 2022	EX-4.2	Form of Underwriter’s Warrant, filed as exhibit 4.2 to the Form S-1/A filed on January 18, 2022 and incorporated herein by reference. Exhibit 4.2 UNDERWRITER COMMON STOCK PURCHASE WARRANT NUVECTIS PHARMA, INC. Warrant Shares: Issue Date:, 2022 Initial Exercise Date: , 2022 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
January 18, 2022	FWP	1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology JANUARY 2022 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology Issuer Free Writing Prospectus Filed pursuan 1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology JANUARY 2022 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333 - 260099 Forward - Looking Statements Certain statements in this presentation constitute ?forward - looking statements? within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended .
November 30, 2021	CORRESP	November 30, 2021 November 30, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 30, 2021	S-1/A	As filed with the U.S. Securities and Exchange Commission on November 30, 2021. S-1/A 1 tm2134024-1s1a.htm S-1/A TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on November 30, 2021. Registration No. 333-260099 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware
November 30, 2021	CORRESP	November 30, 2021 November 30, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 26, 2021	CORRESP	ThinkEquity LLC 17 State Street, 22nd Floor New York, New York 10004 ThinkEquity LLC 17 State Street, 22nd Floor New York, New York 10004 November 26, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 26, 2021	CORRESP	VIA EDGAR November 26, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 9, 2021	FWP	Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333-260099 1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology NOVEMBER 2021 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology Forward - Looking Statements Certain statements in this presentation constitute ?forward - looking statements? within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended .
November 8, 2021	S-1/A	As filed with the U.S. Securities and Exchange Commission on November 8, 2021. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on November 8, 2021. Registration No. 333-260099? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-240
November 4, 2021	FWP	Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333-260099 1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology NOVEMBER 2021 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology Forward - Looking Statements Certain statements in this presentation constitute ?forward - looking statements? within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended .
November 2, 2021	FWP	Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration Number 333-260099 1 SEPTEMBER 2021 Innovative Precision - Medicine for Serious Conditions Of Unmet Medical Need in Oncology NOVEMBER 2021 Innovative Precision Medicine for Serious Conditions Of Unmet Medical Need in Oncology Forward - Looking Statements Certain statements in this presentation constitute ?forward - looking statements? within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended .
October 28, 2021	EX-4.2	Form of Warrant, filed as exhibit 4.2 to the Form S-1/A filed on October 28, 2021 and incorporated herein by reference. Exhibit 4.2 FORM OF WARRANT THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFEC
October 28, 2021	S-1/A	As filed with the U.S. Securities and Exchange Commission on October 28, 2021. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 28, 2021. Registration No. 333-260099? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-240
October 28, 2021	EX-10.4	EMPLOYMENT AGREEMENT ? Exhibit 10.4 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of May 1, 2021 (the ?Effective Date?) by and between Shay Shemesh (?Employee?) and Nuvectis Pharma,?Inc., a Delaware corporation (the ?Company?). The Employee and the Company are hereinafter referred to individually as a ?Party? and together as the ?Parties.? ? WITNESSETH: ? WHEREAS, the Company
October 28, 2021	EX-1.1	Form of Underwriting Agreement.♦ Exhibit 1.1 UNDERWRITING AGREEMENT between NUVECTIS PHARMA, INC. and THINKEQUITY LLC as Representative of the Several Underwriters Nuvectis Pharma, Inc. UNDERWRITING AGREEMENT New York, New York October, [•], 2021 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, Nuvec
October 28, 2021	EX-10.2	EMPLOYMENT AGREEMENT EX-10.2 4 tm2123577d12ex10-2.htm EXHIBIT 10.2 Exhibit 10.2   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of May 1, 2021 (the “Effective Date”) by and between Ron Bentsur (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Par
October 28, 2021	EX-10.3	EMPLOYMENT AGREEMENT EX-10.3 5 tm2123577d12ex10-3.htm EXHIBIT 10.3 Exhibit 10.3   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of May 1, 2021 (the “Effective Date”) by and between Enrique Poradosu (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the
October 21, 2021	EX-10.4	Executive Employment Agreement with Shay Shemesh. EX-10.4 7 tm2123577d9ex10-4.htm EXHIBIT 10.4   Exhibit 10.4   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [●], 2021 (the “Effective Date”) by and between Shay Shemesh (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Par
October 21, 2021	EX-3.1	Form of Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc.♦ EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. Nuvectis Pharma, Inc., a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the ?Corporation?) does hereby certify as follows: 1. The name of the Corp
October 21, 2021	EX-10.3	Executive Employment Agreement with Enrique Poradosu. Exhibit 10.3 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of [?], 2021 (the ?Effective Date?) by and between Enrique Poradosu (?Employee?) and Nuvectis Pharma,?Inc., a Delaware corporation (the ?Company?). The Employee and the Company are hereinafter referred to individually as a ?Party? and together as the ?Parties.? ? WITNESSETH: ? WHEREAS, the Company
October 21, 2021	EX-10.5	Executive Employment Agreement with Uri Ben-Or, dated March 29, 2021. Exhibit 10.5 Date: March 29, 2021 The Agreement: CFO Direct's Proposal - Preparing Centry Pharma, Inc. (the Company) for its IPO on the NASDAQ ü Acting as the Company Controller and CFO, including management of the Company's accounting books (e.g. Quickbooks), payroll, benefits, and healthcare, as appropriate, in Israel and the US; ü Assist the Company in picking the financial auditor; ü Preparing
October 21, 2021	EX-10.7	License Agreement between Nuvectis Pharma, Inc. and The University Court of the University of Edinburgh, dated August 26, 2021. ♦ Exhibit 10.7 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[**].? LICENCE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH and NUVECTIS PHARMA, INC. University of Edinburgh Legal Services Old College South Bridg
October 21, 2021	EX-10.2	Executive Employment Agreement with Ron Bentsur. Exhibit 10.2   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [●], 2021 (the “Effective Date”) by and between Ron Bentsur (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Parties.”   WITNESSETH:   WHEREAS, the Company and
October 21, 2021	EX-3.2	Form of Amended and Restated Bylaws of Nuvectis Pharma, Inc.♦ EXHIBIT 3.2 amended and restated BYLAWS OF nuVectis PHARMA, INC. amended and restated BYLAWS OF nuvectis PHARMA, inc. Article I OFFICES Section 1.1 Offices. The address of the registered office of Nuvectis Pharma, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The Corporation may have other off
October 21, 2021	S-1/A	As filed with the U.S. Securities and Exchange Commission on October 20, 2021. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 20, 2021. Registration No. 333-??????? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-240
October 21, 2021	EX-4.1	Form of Common Stock Certificate.♦ Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Number ****** Shares ****** NUVECTIS PHARMA, INC. Total Authorized Capital Stock of 65,000,000 shares, par value US $.00001 This is to certify that is the registered holder of shares of Common Stock, par value $0.00001 per share, of Nuvectis Pharma, Inc., hereinafter designated the "Corporation", transferable on the share registe
October 21, 2021	EX-10.6	License Agreement between Nuvectis Pharma, Inc. and CRT Pioneer Fund LP dated May 19, 2021. *♦ CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
October 20, 2021	CORRESP	90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 Matthew W. Mamak Direct Dial: 212-210-1256 Email: [email protected] October 20, 2021 VIA: ELECTRONIC MAIL Margaret Schwartz Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Nuvectis Pharma, Inc. Registration Statement on Form S-1 Filed October 6, 2021 CIK No. 0001875558 Dear Ms. Schwartz: On b
October 6, 2021	EX-4.1	Form of Common Stock Certificate. EX-4.1 4 tm2123577d3ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Number ****** Shares ****** NUVECTIS PHARMA, INC. Total Authorized Capital Stock of 500,000 shares, par value US $.00001 This is to certify that is the registered holder of shares of Common Stock, par value $0.00001 per share, of Nuvectis Pharma, Inc., hereinafter designated the "Corporat
October 6, 2021	EX-10.2	Executive Employment Agreement with Ron Bentsur, filed as exhibit 10.2 to the Form S-1/A filed on October 6, 2021 and incorporated herein by reference. # Exhibit?10.2 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of [?], 2021 (the ?Effective Date?) by and between Ron Bentsur (?Employee?) and Nuvectis Pharma,?Inc., a Delaware corporation (the ?Company?). The Employee and the Company are hereinafter referred to individually as a ?Party? and together as the ?Parties.? ? WITNESSETH: ? WHEREAS, the Company and
October 6, 2021	EX-10.4	Executive Employment Agreement with Shay Shemesh, filed as exhibit 10.4 to the Form S-1/A filed on October 6, 2021 and incorporated herein by reference. #   Exhibit 10.4   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [●], 2021 (the “Effective Date”) by and between Shay Shemesh (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Parties.”   WITNESSETH:   WHEREAS, the Company a
October 6, 2021	EX-10.3	Executive Employment Agreement with Enrique Poradosu, filed as exhibit 10.3 to the Form S-1/A filed on October 6, 2021 and incorporated herein by reference. # EX-10.3 7 tm2123577d3ex10-3.htm EXHIBIT 10.3 Exhibit 10.3   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [●], 2021 (the “Effective Date”) by and between Enrique Poradosu (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “P
October 6, 2021	EX-10.1	Global Equity Incentive Plan. Exhibit 10.1 NUVECTIS PHARMA, Inc. Global Equity Incentive Plan (2021) 1. Name And Purpose. 1.1 This plan, which has been adopted by the Board of Directors of Nuvectis Pharma, Inc. (the “Corporation”), shall be known as the Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021), as amended from time to time (the “Plan”). 1.2 The purposes of the Plan are to attract and retain the best available
October 6, 2021	EX-10.5	License Agreement between Nuvectis Pharma, Inc. and CRT Pioneer Fund LP dated May 19, 2021, filed as exhibit 10.5 to the Form S-1/A filed on October 6, 2021 and incorporated herein by reference. EX-10.5 9 tm2123577d3ex10-5.htm EXHIBIT 10.5 EXHIBIT 10.5 (1) CRT PIONEER FUND LP AND (2) CENTRY PHARMA, INC. LICENCE AGREEMENT This Licence Agreement (the “Agreement”) is entered into on 19 May 2021 (the “Effective Date”) by and between: (1) CRT PIONEER FUND LP, a limited partnership established in England and Wales under number LP 14391 with its registered office at [*] (“CPF”), acting by its
October 6, 2021	S-1	Power of Attorney (included on signature page). TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 6, 2021. Registration No. 333-??????? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933? ? Nuvectis Pharma, Inc. (Exact name of Registrant as specified in its charter) ? ? Delaware ? ? 2834 ? ? 86-2405608 ? ? (State of i
October 6, 2021	EX-3.1	Form of Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc. EX-3.1 2 tm2123577d3ex3-1.htm EXHIBIT 3.1 EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. Nuvectis Pharma, Inc., a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby c
October 6, 2021	EX-10.6	License Agreement between Nuvectis Pharma, Inc. and The University Court of the University of Edinburgh, dated August 26, 2021, filed as exhibit 10.6 to the Form S-1/A filed on October 6, 2021 and incorporated herein by reference. EX-10.6 10 tm2123577d6ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[*].” LICENCE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH and NUVECTIS PHARMA, INC. University of Ed
October 6, 2021	CORRESP	90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 Matthew W. Mamak Direct Dial: 212-210-1256 Email: [email protected] October 6, 2021 VIA: ELECTRONIC MAIL Margaret Schwartz Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Nuvectis Pharma, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted September 20, 2021 CIK No. 000
October 6, 2021	EX-3.2	Form of Amended and Restated Bylaws of Nuvectis Pharma, Inc. EXHIBIT 3.2 amended and restated BYLAWS OF nuVectis PHARMA, INC. amended and restated BYLAWS OF nuvectis PHARMA, inc. Article I OFFICES Section 1.1 Offices. The address of the registered office of Nuvectis Pharma, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The Corporation may have other off
September 20, 2021	EX-4.1	INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE EX-4.1 4 filename4.htm Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Number ****** Shares ****** NUVECTIS PHARMA, INC. Total Authorized Capital Stock of 500,000 shares, par value US $.00001 This is to certify that is the registered holder of shares of Common Stock, par value $0.00001 per share, of Nuvectis Pharma, Inc., hereinafter designated the "Corporation", transferable
September 20, 2021	DRSLTR	90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 90 Park Avenue New York, NY 10016 212-210-9400 \| Fax: 212-210-9444 Matthew W. Mamak Direct Dial: 212-210-1256 Email: [email protected] September 20, 2021 VIA: ELECTRONIC MAIL Margaret Schwartz Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Nuvectis Pharma, Inc. Draft Registration Statement on Form S-1 Submitted July 30, 2021 CIK No. 0001875558 Dear Ms. Schw
September 20, 2021	EX-10.3	EMPLOYMENT AGREEMENT Exhibit 10.3 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of [?], 2021 (the ?Effective Date?) by and between Enrique Poradosu (?Employee?) and Nuvectis Pharma,?Inc., a Delaware corporation (the ?Company?). The Employee and the Company are hereinafter referred to individually as a ?Party? and together as the ?Parties.? ? WITNESSETH: ? WHEREAS, the Company
September 20, 2021	EX-10.6	LICENCE AGREEMENT EX-10.6 9 filename9.htm EXHIBIT 10.6 (1) CRT PIONEER FUND LP AND (2) CENTRY PHARMA, INC. LICENCE AGREEMENT This Licence Agreement (the “Agreement”) is entered into on 19 May 2021 (the “Effective Date”) by and between: (1) CRT PIONEER FUND LP, a limited partnership established in England and Wales under number LP 14391 with its registered office at [***] (“CPF”), acting by its general partner, CRT
September 20, 2021	EX-3.1	SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. EX-3.1 2 filename2.htm EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUVECTIS PHARMA, INC. Nuvectis Pharma, Inc., a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify as follows:
September 20, 2021	EX-10.1	NUVECTIS PHARMA, Inc. Global Equity Incentive Plan (2021) EX-10.1 5 filename5.htm Exhibit 10.1 NUVECTIS PHARMA, Inc. Global Equity Incentive Plan (2021) 1. Name And Purpose. 1.1 This plan, which has been adopted by the Board of Directors of Nuvectis Pharma, Inc. (the “Corporation”), shall be known as the Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021), as amended from time to time (the “Plan”). 1.2 The purposes of the Plan are to attract and re
September 20, 2021	EX-3.2	amended and restated nuVectis PHARMA, INC. amended and restated BYLAWS OF nuvectis PHARMA, inc. Article I OFFICES EX-3.2 3 filename3.htm EXHIBIT 3.2 amended and restated BYLAWS OF nuVectis PHARMA, INC. amended and restated BYLAWS OF nuvectis PHARMA, inc. Article I OFFICES Section 1.1 Offices. The address of the registered office of Nuvectis Pharma, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be at 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The Corpora
September 20, 2021	EX-10.4	EMPLOYMENT AGREEMENT EX-10.4 8 filename8.htm   Exhibit 10.4   EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [●], 2021 (the “Effective Date”) by and between Shay Shemesh (“Employee”) and Nuvectis Pharma, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Parties.”   WITNESSETH:
September 20, 2021	EX-10.2	EMPLOYMENT AGREEMENT Exhibit?10.2 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of [?], 2021 (the ?Effective Date?) by and between Ron Bentsur (?Employee?) and Nuvectis Pharma,?Inc., a Delaware corporation (the ?Company?). The Employee and the Company are hereinafter referred to individually as a ?Party? and together as the ?Parties.? ? WITNESSETH: ? WHEREAS, the Company and
September 20, 2021	DRS/A	As confidentially submitted to the Securities and Exchange Commission on September 20, 2021. This Amendment No. 1 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein r TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on September 20, 2021.
September 20, 2021	EX-10.7	LICENCE AGREEMENT THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH NUVECTIS PHARMA, INC. University of Edinburgh Legal Services Old College South Bridge Edinburgh, EH8 9YL Ref: [*] EX-10.7 10 filename10.htm Exhibit 10.7 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[*].” LICENCE AGREEMENT between THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH and NUVECTIS PHARMA, INC. University of Edinburgh Legal Servic
July 30, 2021	DRS	As confidentially submitted to the Securities and Exchange Commission on July 30, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on July 30, 2021.

NVCT / Nuvectis Pharma, Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)